NEW YORK (360Dx) – With a plan to eventually launch a broad menu of tests using its disposable microfluidic platform, Group K Diagnostics is carefully preparing its entry into clinical point-of-care diagnostic testing.
The Philadelphia-based startup has a pipeline for product launches planned through 2020, but it will look to achieve US regulatory clearance in a methodical manner, Group K's Chief Strategy Officer Emilia Lopez-Ona said in an interview.